Evaluation of Clinical Characteristics and Biomarkers after Endovenous Foam Sclerotherapy for Venous Disorders
|Suman Rathbun1*, Ryan Zander2, Richard A Marlar3, Pravina Kota2, Ying Zhang2, Thomas Whitsett1 and Julie A Stoner2|
|1Department of Medicine, Cardiovascular section, University of Oklahoma Health Sciences Center, USA|
|2Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, USA|
|3Department of Pathology, University of Oklahoma Health Sciences Center, USA|
|*Corresponding Author :||Suman W Rathbun
Vascular Medicine, University of Oklahoma Health Sciences Center
920 Stanton L Young Blvd. WP 3120, OK 73014, USA
E-mail: [email protected]
|Received date: March 30, 2016; Accepted date: April 20, 2016; Published date: April 27, 2016|
|Citation: Rathbun S, Zander R, Marlar RA, Kota P, Zhang Y, et al. (2016) Evaluation of Clinical Characteristics and Biomarkers after Endovenous Foam Sclerotherapy for Venous Disorders. J Clin Trials 6:263. doi:10.4172/2167-0870.1000263|
|Copyright: © 2016 Rathbun S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Objective: Endovenous foam sclerotherapy (EFS) is widely performed in the U.S, but there is a paucity of studies evaluating clinical predictors of outcomes, including biomarkers, in patients with venous disorders.
Methods: Patients undergoing EFS monotherapy for venous disorders were enrolled. Evaluation at baseline, 1 week, 12 weeks, and 26 weeks included clinical characteristics and biomarker analysis.
Results: 100 patients with venous disease were treated. At one week follow-up, 44% underwent a second injection. At 3 months, 100% of patients had obliteration of at least 80% of their affected veins, and 96% reported improved venous stasis symptoms. Adverse events were minor and deep vein thrombosis was found 4 patients at 3 months. D-dimer levels were significantly higher at week one, but returned to baseline by week 12; fibrin monomer decreased and PPL increased at one week and 3 months relative to baseline.
Conclusion: EFS monotherapy is effective in treating signs and symptoms of venous disease with few adverse effects. D-dimer levels are significantly associated with obliteration of venous segments suggesting an association between vein obliteration and activation of coagulation.